Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Halkes, P.H.A.; Gray, Laura J.; Bath, Philip M.W.; Diener, Hans-Christoph; Guiraud-Chaumeil, B. (2008)
Publisher: BMJ
Languages: English
Types: Article
Objectives: Our aim was to study the effect of combination therapy with aspirin and dipyridamole (A+D) over aspirin alone (ASA) in secondary prevention after transient \ud ischemic attack or minor stroke of presumed arterial origin and to perform subgroup analyses to identify patients that might benefit most from secondary prevention with A+D.\ud Data sources: The previously published meta-analysis of individual patient data was updated with data from ESPRIT (N=2,739); trials without data on the comparison of A+D versus ASA were excluded.\ud Review methods: A meta-analysis was performed using Cox regression, including several subgroup analyses and following baseline risk stratification.\ud Results: A total of 7,612 patients (5 trials) were included in the analyses, 3,800 allocated to A+D and 3,812 to ASA alone. The trial-adjusted hazard ratio for the composite event of vascular death, non-fatal myocardial infarction and non-fatal stroke was 0.82 (95% confidence interval 0.72-0.92). Hazard ratios did not differ in subgroup analyses based on age, sex, qualifying event, hypertension, diabetes, previous stroke, ischemic heart disease,\ud aspirin dose, type of vessel disease and dipyridamole formulation, nor across baseline risk strata as assessed with two different risk scores. A+D were also more effective than ASA alone in preventing recurrent stroke, HR 0.78 (95% CI 0.68 – 0.90).\ud Conclusion: The combination of aspirin and dipyridamole is more effective than aspirin alone in patients with TIA or ischemic stroke of presumed arterial origin in the secondary\ud prevention of stroke and other vascular events. This superiority was found in all subgroups and was independent of baseline risk. ---------------------------7dc3521430776\ud Content-Disposition: form-data; name="c14_creators_1_name_family"\ud \ud Halkes
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Warlow CP. Secondary prevention of stroke. Lancet 1992;339:724-7.
    • 2. Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J.Neurol.Neurosurg.Psychiatry 1996;60:197-9.
    • 3. Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J.Neurol.Neurosurg.Psychiatry 1999;66:255.
    • 4. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
    • 5. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J.Neurol.Sci. 1996;143:1-13.
    • 6. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
    • 7. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N.Engl.J.Med. 2006;354:1706-17.
    • 8. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-7.
    • 9. The Stroke Prevention in Reversible Ischaemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann.Neurol. 1997;42:857-65.
    • Mohr JP, Thompson JLP, Lazar RM, et al, for the Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N.Engl.J.Med. 2001;345:1444-51.
    • 11. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al, for the Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N.Engl.J.Med. 2005;352:1305-16.
    • 12. Algra A, De Schryver ELLM, van Gijn J, et al. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane.Database.Syst.Rev. 2006;3:CD001342.
    • 13. The ESPRIT Study Group. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol. 2007;6:115-24.
    • 14. Guiraud-Chaumeil B, Rascol A, David J, et al. Prévention des récidives des accidents vasculaires cérébraux ischémiques par les anti-agrégants plaquettaires. Résultats d'un essai thérapique controlé de 3 ans. Rev.Neurol.(Paris) 1982;138:367-85.
    • 15. Bousser MG, Eschwege E, Haguenau M, et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983;14:5-14.
    • 16. American-Canadian Co-operative Study group. Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. Stroke 1985;16:406-15.
    • 17. Kaye, J. A. A trial to evaluate the relative roles of dipyridamole and aspirin in the prevention of deep vein thrombosis in stroke patients. Bracknell, Berkshire, Boehringer Ingelheim (internal report) . 1990.
    • 18. European Stroke Prevention Study 2. Efficacy and safety data. J.Neurol.Sci. 1997;151 Suppl:S1-77.
    • 19. Algra A, van Gijn J, Koudstaal PJ. Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone? J.Neurol.Neurosurg.Psychiatry 1999;66:557-9.
    • 20. Leonardi-Bee J, Bath PM, Bousser MG, et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke 2005;36:162-8.
    • 21. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1665-73.
    • 22. Ariesen MJ, Algra A, Kappelle LJ. Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2. Stroke 2006;37:134-8.
    • 23. Kappelle LJ, van Latum JC, van Swieten JC, et al, for the Dutch TIA Trial Study Group. Recurrent stroke after transient ischaemic attack or minor ischaemic stroke: does the distinction between small and large vessel disease remain true to type? J.Neurol.Neurosurg.Psychiatry 1995;59:127-31.
    • 24. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N.Engl.J.Med. 1991;325:1261-6.
    • 25. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke 1993;24:543-8.
    • 26. The Dutch TIA Trial Study Group. Predictors of major vascular events in patients with a transient ischemic attack or nondisabling stroke. Stroke 1993;24:527-31.
    • 27. Smith CT, Williamson PR, Marson AG. Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. Stat.Med. 2005;24:1307-19.
    • 28. Dippel DW, Koudstaal PJ. We need stronger predictors of major vascular events in patients with a recent transient ischemic attack or nondisabling stroke. Dutch TIA Trial Study Group. Stroke 1997;28:774-6.
    • 29. Diener HC. Modified-release dipyridamole combined with aspirin for secondary stroke prevention. Aging Health 2005;1:19-26.
    • 30. Sacco RL, Sivenius J, Diener HC. Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations. Arch.Neurol. 2005;62:403-8.
    • 31. Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 1993;341:418-22.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article